The Expression of PAX5, P53 Immunohistochemistry and P53 Mutation Analysis in Superficial Bladder Carcinoma Tissue. Correlation with Pathological Findings and Clinical Outcome

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2003 Oct 28

PMID 14577491

Citations 5

Authors

M Babjuk

V Soukup

J Mares

J Duskova

Z Sedlacek

M Trkova

L Pecen

J Dvoracek

T Hanus

R Kocvara

J Novak

C Povysil

Affiliations

Soon will be listed here.

Abstract

Objectives: The expression pattern of PAX5 in the tissue of superficial bladder transitional cell carcinoma (TCC), its prognostic value and its correlation with p53 immunohistochemistry and p53 mutation analysis were evaluated.

Methods: Study comprised 61 patients with histologically confirmed superficial bladder TCC. Expression level of PAX5 mRNA was investigated using reverse transcriptase-polymerase chain reaction (RT-PCR) and determined semiquantitatively. The presence of p53 mutations was determined by SSCP and confirmed by direct sequencing. The p53 immunohistochemistry was performed with DO1 antibody and semiquantitatively evaluated using HSCORE (HS) method. As the control group for the evaluation of the PAX5 expression served 8 men with benign prostatic hyperplasia.

Results: PAX5 expression was found in 50 patients with bladder TCC but in no patient from the control group. Its quantity however correlated neither with the stage nor with the grade of the tumor. P53 mutation was confirmed only in 1 patient with pTaG2 tumor in exon 5 (deletion of proline 128). On the contrary, positive immunohistochemical staining of p53 was detected in most patients. Using the cutoff value of HS 200, 56.9% of patients showed p53 overexpression. Quantity of p53 immunochistochemical positivity did not correlate with the quantity of PAX5 expression. Using the cutoff values of HS 200 for p53 and of 0.2 for PAX5, 7 of 8 patients with future progression had p53 and 4 had PAX5 overexpression respectively.

Conclusion: The expression of gene PAX5 is a frequent event in superficial TCC of the bladder.

Citing Articles

Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.

Chin F, Chan S, Veerakumarasivam A Diagnostics (Basel). 2023; 13(16).

PMID: 37627900 PMC: 10453580. DOI: 10.3390/diagnostics13162641.

Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression.

Zhao L, Li S, Gan L, Li C, Qiu Z, Feng Y J Cell Mol Med. 2016; 20(5):842-54.

PMID: 26843424 PMC: 4831360. DOI: 10.1111/jcmm.12768.

Spleen-specific isoforms of Pax5 and Ataxin-7 as potential proteomic markers of lymphoma-affected spleen.

Bharti B, Mishra R Mol Cell Biochem. 2015; 402(1-2):181-91.

PMID: 25573326 DOI: 10.1007/s11010-014-2325-7.

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

Mhawech-Fauceglia P, Saxena R, Zhang S, Terracciano L, Sauter G, Chadhuri A J Clin Pathol. 2006; 60(6):709-14.

PMID: 16837628 PMC: 1955074. DOI: 10.1136/jcp.2006.039917.

A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

Kelsey K, Hirao T, Schned A, Hirao S, Devi-Ashok T, Nelson H Br J Cancer. 2004; 90(8):1572-6.

PMID: 15083187 PMC: 2409723. DOI: 10.1038/sj.bjc.6601748.

References

Sarkis A, Dalbagni G, Cordon-Cardo C, Zhang Z, Sheinfeld J, Fair W . Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993; 85(1):53-9. DOI: 10.1093/jnci/85.1.53. View

Heney N, Ahmed S, FLANAGAN M, Frable W, Corder M, Hafermann M . Superficial bladder cancer: progression and recurrence. J Urol. 1983; 130(6):1083-6. DOI: 10.1016/s0022-5347(17)51695-x. View

Llopis J, Alcaraz A, Ribal M, Sole M, Ventura P, Barranco M . p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol. 2000; 37(6):644-53. DOI: 10.1159/000020232. View

Abdel-Fattah R, Challen C, Griffiths T, Robinson M, Neal D, Lunec J . Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer. 1998; 77(12):2230-8. PMC: 2150401. DOI: 10.1038/bjc.1998.371. View

Adshead J, Ogden C, Penny M, Stuart E, Kessling A . The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU Int. 1999; 83(9):1039-44. DOI: 10.1046/j.1464-410x.1999.00052.x. View

Gontero P, Casetta G, Zitella A, BALLARIO R, Pacchioni D, Magnani C . Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol. 2000; 38(3):287-96. DOI: 10.1159/000020295. View

Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter V, Cordon-Cardo C . Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res. 1994; 54(11):2848-51. View

McCarty Jr K, Miller L, Cox E, Konrath J, McCarty Sr K . Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985; 109(8):716-21. View

Grompe M . The rapid detection of unknown mutations in nucleic acids. Nat Genet. 1993; 5(2):111-7. DOI: 10.1038/ng1093-111. View

10.

Shigyo M, Sugano K, Fukayama N, Taniguchi T, Tobisu K, Fujimoto H . Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer. 1998; 78(4):425-9. DOI: 10.1002/(sici)1097-0215(19981109)78:4<425::aid-ijc6>3.0.co;2-w. View

11.

Schmitz-Drager B, Goebell P, Ebert T, Fradet Y . p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. Eur Urol. 2000; 38(6):691-9;discussion 700. DOI: 10.1159/000020364. View

12.

Reiher F, Ozer O, Pins M, Jovanovic B, Eggener S, Campbell S . p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol. 2002; 167(3):1469-74. View

13.

Stuart E, Kioussi C, Aguzzi A, Gruss P . PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res. 1995; 1(2):207-14. View

14.

Levine A . p53, the cellular gatekeeper for growth and division. Cell. 1997; 88(3):323-31. DOI: 10.1016/s0092-8674(00)81871-1. View

15.

Nutt S, Thevenin C, Busslinger M . Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology. 1998; 198(1-3):227-35. DOI: 10.1016/S0171-2985(97)80043-5. View

16.

Serth J, Kuczyk M, Bokemeyer C, Hervatin C, Nafe R, Tan H . p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer. 1995; 71(1):201-5. PMC: 2033435. DOI: 10.1038/bjc.1995.41. View

17.

Cairns P, Shaw M, Knowles M . Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene. 1993; 8(4):1083-5. View

18.

Gardiner R, Walsh M, Allen V, Rahman S, Samaratunga M, Seymour G . Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol. 1994; 73(5):526-32. DOI: 10.1111/j.1464-410x.1994.tb07638.x. View

19.

Lamm D . Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992; 19(3):573-80. View

20.

Stuart E, Haffner R, Oren M, Gruss P . Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 1995; 14(22):5638-45. PMC: 394679. DOI: 10.1002/j.1460-2075.1995.tb00251.x. View